Charli Sanders

Senior Vice President, Regulatory Affairs at LFB S.A.

Dr. Charli Sanders joined LFB USA as Senior Vice President, Regulatory Affairs in January 2018. Dr. Sanders brings extensive strategic regulatory affairs, medical, and pharmacovigilance expertise to LFB-USA that includes more than 18 years of pharmaceutical management experience. Her experience in global drug development, clinical research and regulatory affairs includes interactions world-wide with regulators, scientific leaders, and major pharmaceutical/biotech companies. Dr. Sander’s therapeutic experience in oncology, neuroscience, analgesia, immunology and pediatrics is well-aligned with our innovative therapeutic focus.

Dr. Sanders trained in Pediatrics and has held teaching faculty appointments at the Children’s Hospital of Los Angeles (USC), Morgan Stanley Children’s Hospital (Columbia University Medical Center), Children’s Hospital of Boston (Harvard University) and Yale University. She received her Medical Degree from the University of Pennsylvania School of Medicine and as well as her undergraduate degree through Penn's University Scholars' Program which enabled her to conduct early nonclinical translational research in demyelination disorders of the central and peripheral nervous systems.

Prior to joining LFB USA, Dr. Sanders was Senior Vice President, Global Regulatory Affairs for Kadmon Pharmaceutical Holdings, Inc. where she was responsible for Global Medical and Regulatory Affairs including strategic, clinical, CMC and pharmacovigilance compliance. Prior to Kadmon, Dr. Sanders was employed as Vice President Global Regulatory Affairs, Compliance and Medical Writing at Premier Research. In her capacity as VP at Premier, Dr. Sanders represented small-to-large pharma/device companies in their quests to attain first-to-market product authorizations and commercialization of their medical and health care products. Dr. Sanders’ formative industry career achievements included successful advancing strategic regulatory and product development leadership roles at Merck Sharp & Dohme (MSD), Daiichi Sankyo, and Barr-Duramed (Teva). Dr. Sanders is able to leverage her broad career experiences, both in global medical and regulatory management to bring a wealth of knowledge to the LFB organization.